These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
597 related articles for article (PubMed ID: 19424970)
1. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain. Wittenbrink M; Spreu J; Steinle A Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970 [TBL] [Abstract][Full Text] [Related]
2. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Waldhauer I; Steinle A Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567 [TBL] [Abstract][Full Text] [Related]
3. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Song H; Kim J; Cosman D; Choi I Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603 [TBL] [Abstract][Full Text] [Related]
4. Four novel ULBP splice variants are ligands for human NKG2D. Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572 [TBL] [Abstract][Full Text] [Related]
5. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318 [TBL] [Abstract][Full Text] [Related]
6. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848 [TBL] [Abstract][Full Text] [Related]
7. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262 [TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645 [TBL] [Abstract][Full Text] [Related]
9. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Chalupny NJ; Rein-Weston A; Dosch S; Cosman D Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166 [TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710 [TBL] [Abstract][Full Text] [Related]
12. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Diefenbach A; Hsia JK; Hsiung MY; Raulet DH Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935 [TBL] [Abstract][Full Text] [Related]
13. NKG2D and Related Immunoreceptors. Strong RK; McFarland BJ Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864 [TBL] [Abstract][Full Text] [Related]
14. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428 [TBL] [Abstract][Full Text] [Related]
15. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. Park MJ; Bae JH; Chung JS; Kim SH; Kang CD Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289 [TBL] [Abstract][Full Text] [Related]
16. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
17. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853 [TBL] [Abstract][Full Text] [Related]
18. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells. Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646 [TBL] [Abstract][Full Text] [Related]
19. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980 [TBL] [Abstract][Full Text] [Related]
20. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]